塞托溴铵治疗频繁急性加重表型COPD的外科择期手术患者的疗效和免疫因子的影响

doi:10.3969/j.issn.1009-976X.2021.02.018

摘要/Abstract

摘要： 目的探讨塞托溴铵治疗频繁急性加重慢性阻塞性肺疾病（COPD）患者的效果及对血清PD-1/PD-L1、CC16、呼出气冷凝液中炎症指标的影响。方法选取2018年1月~2020年6月入院的118例待实施外科择期手术的频繁急性加重COPD患者作为研究对象,根据患者就诊顺序分为联合组、常规组各59例,常规组采用抗感染、支持治疗+丙酸氟替卡松+特布他林治疗,联合组在常规组基础上加用塞托溴铵;对比两组患者治疗前后肺功能、血气参数、外周血程序死亡受体-1（PD-1）、细胞程序死亡-配体1（PD-L1）、呼出气冷凝液炎症相关指标、血清CC16水平的差异。结果治疗前,两组患者间肺功能指标、血气指标、血清PD-1/PD-L1/CC16水平、呼出气冷凝液中炎症介质（IL-17、IL-10、8-iso-PG）的差异无统计学意义（P>0.05）。治疗后联合组FVC、FEV1、PEF较常规组有统计学意义（P<0.05）,联合组PaCO₂值较常规组低（P<0.05）。治疗后联合组外周血PD-1、PD-L1水平低于常规组。联合组呼出气冷凝的IL-17、8-iso-PG低于常规组（P<0.05）,但联合组呼出气冷凝的IL-10高于常规组（P<0.05）。同时发现,联合组患者疗效优于常规组（P<0.05）。结论塞托溴铵+丙酸氟替卡松+特布他林结合基础方法治疗频繁急性加重COPD患者,更有助于改善肺功能及血气水平,有助于减少手术的禁忌症。

关键词: 塞托溴铵, 慢性阻塞性肺疾病, 频繁急性加重, 丙酸氟替卡松, 特布他林

Abstract: Objective To explore the effect of Tiotropium Bromide onon the clinical efficacy and immune factors in patients with frequent acute exacerbations of COPD. Methods A total of 118 frequent acute COPD patients from January 2018 to June 2020 were selected as the research objects, and they were divided into a combination group and a routine group with 59 cases in accordance with the order of treatment. The routine group was treated with anti-infection, supportive treatment and Fluticasone propionate/terbutaline; Tiotropium Bromide was added to the conventional group in the combination group. The differences in pulmonary function, blood gas parameters, peripheral blood programmed death-1 （PD-1）, programmed cell death-ligand 1 （PD-L1）, exhaled breath condensate inflammation-related indicators, and serum CC16 levels before and after treatment were compared between the two groups. Results Before treatment, there was no significant difference in various pulmonary function indicators, blood gas indicators, the serum levels of PD-1/PD-L1/CC16, and the inflammatory mediators in exhaled breath condensate （IL-17, IL-10, and 8-iso-PG） between the two groups （P>0.05）. After treatment, the FVC, FEV1 and PEF in the combined group were statistically significantly higher than those in the conventional group （P<0.05）, and the PaCO₂ value in the combined group was lower than that in the conventional group （P<0.05）. After treatment, the PD-1 and PD-L1 levels in the peripheral blood of the combined group were lower than those in the conventional group. In additional, the IL-17 and 8-iso-PG of exhaled breath condensation in the combined group were lower than those in the conventional group （P<0.05）, but IL-10 of exhaled breath condensation in the combined group was higher than that in the conventional group （P<0.05）. Meanwhile, the efficacy was evaluated after treatment, and the efficacy of the patients in the combined group was better than that in the conventional group （P<0.05）. Conclusion The combination of Tiotropium Bromide/Fluticasone Propionate/Terbutaline and basic methods in the treatment of frequent acute exacerbations COPD patients is beneficial to alleviate the degree of inflammatory response, improve lung function and blood gas level, and expects to help reduce the contraindications of surgery.

Key words: Tiotropium Bromide, chronic obstructive pulmonary disease, frequent acute exacerbation, Fluticasone propionate, terbutaline

中图分类号:

R655

刘林生, 姚伟平, 陈迪伦, 蔡迪, 刘小利. 塞托溴铵治疗频繁急性加重表型COPD的外科择期手术患者的疗效和免疫因子的影响[J]. 岭南现代临床外科, 2021, 21(02): 217-221.

LIU Lin-sheng, YAO Wei-ping, CHEN Di-lun, CAI Di, LIU Xiao-li. The effect of setropium bromide on frequent acute exacerbations of COPD for improvement of lung function and immune factors regulation in the elective surgical patients with frequent acute exacerbations of COPD[J]. Lingnan Modern Clinics In Surgery, 2021, 21(02): 217-221.

参考文献

[1] Lee AHY, Snowden CP, Hopkinson NS, Pattinson KTS.Pre-operative optimisation for chronic obstructive pulmonary disease: a narrative review[J]. Anaesthesia, 2021, 76(5): 681-694.
[2] Meek P, Lareau S, Fahy B, Austergard E.Surgery for Chronic Obstructive Pulmonary Disease[J]. Am J Respir Crit Care Med, 2019, 200(3): P5-P6.
[3] WHO. Mortality and global health estimates [EB/OL].[2020-11-21][2020-12-23]. https://www.who. int/data/gho/ data/themes/mortality-and-global-health-estimates.
[4] 中华医学会, 中华医学会杂志社, 中华医学会全科医学分会, 等. 慢性阻塞性肺疾病基层诊疗指南(2018年)[J]. 中华全科医师杂志, 2018, 17(11): 856-870.
[5] Fernandez-Bustamante A, Frendl G, Sprung J, et al.Postoperative pulmonary complications, early mortality, and hospital stay following noncardiothoracic surgery: a multicenter study by the perioperative research network investigators[J]. JAMA Surg, 2017, 152(2): 157-166.
[6] Yamana I, Takeno S, Hashimoto T, et al.Randomized controlled study to evaluate the efficacy of a preoperative respiratory rehabilitation program to prevent postoperative pulmonary complications after esophagectomy[J]. Dig Surg, 2015, 32(5): 331-337.
[7] ZhouY, Zhong NS, Li X, et al. Tiotropium in early-stage chronic obstructive pulmonary disease[J]. N Engl J Med, 2017, 377(10): 923-935.
[8] Halpin DMG, Criner GJ, Papi A, et al.Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. The 2020 GOLD Science Committee Report on COVID-19 and Chronic Obstructive Pulmonary Disease[J]. Am J Respir Crit Care Med, 2021, 203(1): 24-36.
[10] Yang X, Huo B, Zhong X, et al.Imbalance between subpopulations of regulatory T cells in patients with acute exacerbation of COPD[J]. COPD, 2017, 14(6): 618-625.
[11] Lugade AA, Bogner PN, Thatcher TH, et al.Cigarette smoke exposure exacerbate slung inflammation and compromises immunity to bacterial infection[J]. J Immunol, 2014, 192(11): 5226-5235.
[12] Bardhan K, Anagnostou T, Boussiotis VA.The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation[J]. Front Immunol, 2016, 7: 550.
[13] 常春, 姚婉贞. 噻托溴铵治疗慢性阻塞性肺疾病十年回顾与展望[J]. 中华结核和呼吸杂志, 2016, 39(3): 217-220.
[14] 叶红, 曹卓. COPD患者血清IL-17、IL-8和TNF-α检测及意义[J]. 放射免疫学杂志, 2013, 26(4): 490-491.
[15] 李小莉, 黄平, 杜秀芳. 慢性阻塞性肺疾病治疗期间呼出气冷凝液中8-异前列腺素、IL-6、IL-10 的变化及与气道炎症的相关性研究[J]. 中国呼吸与危重监护杂志, 2014, 13(5): 445-448.
[16] 陈金亮, 陈建荣, 蔡映云, 等. COPD患者呼出气冷凝液中8-异前列腺素的检测及其意义[J]. 临床肺科杂志, 2011, 16(3): 341-343.
[17] Wutzler S, Lehnert T, Laurer H, et al.Circulating levels of Clara cell protein16 but not surfactant protein D identify and quantify lung damage in patients with multiple injuries[J]. J Trauma, 2011, 71(2): 31-36.
[18] 王秋波. 慢性阻塞性肺疾病患者血清中Clara 细胞分泌蛋白CC16和SP-D浓度与肺功能的相关性[J]. 中国老年学杂志, 2016, 36(12): 2980-2981.
[19] Vestbo J, Edwards LD, Scanlon PD, et al.Changes in forced expiratory volume in 1 second over time in COPD[J]. New Engl J Med, 2011, 365(13): 1184-1192.
[20] Laucho-Contreras ME, Polverino F, Tesfaigzi Y, et al.Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD)[J]. Expert Opin Ther Targets, 2016, 20(7):869-883.